Supplementary Information

Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo

Xi Zhu[1,2,#], Wei Tao[1,#], Danny Liu[1,3], Jun Wu[1,4], Zilei Guo[1], Xiaoyuan Ji[1], Zameer Bharwani[1], Lili Zhao[1,5], Xiaoping Zhao[2], Omid C. Farokhzad[1,6*], Jinjun Shi[1*]

[1] Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

[2] National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai, 201203, China

[3] Department of Chemistry, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada

[4] Department of Biomedical Engineering, School of Engineering, Sun Yet-sen University, Guangzhou, 510006, China

[5] Department of Endoscopy, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China

[6] King Abdulaziz University, Jeddah 21589, Saudi Arabia

# X.Z. and W.T. contributed equally to this work.

* Email: ofarokhzad@bwh.harvard.edu (O.C.F.), *Email: jshi@bwh.harvard.edu (J.S.).



Figure S1. Dissociation kinetics of two lipid-PEGs (DSPE-PEG and DMPE-PEG) from respective NPs in (a) PBS without albumin, and (b) FBS.



Figure S2. *In vitro* silencing efficacy of the PLGA/G0-C14 siRNA NPs without PEGylation.



Figure S3. Uptake kinetics of the PLGA/G0-C14 siRNA NPs without PEGylation by Luc-HeLa cells.



Figure S4. Circulation profile of the PLGA/G0-C14 siRNA NPs without PEGylation after IV injection (siRNA was labeled with fluorophore DY647).